» Articles » PMID: 33759032

Cognitive Enhancement: Unanswered Questions About Human Psychology and Social Behavior

Overview
Journal Sci Eng Ethics
Date 2021 Mar 24
PMID 33759032
Citations 9
Authors
Affiliations
Soon will be listed here.
Abstract

Stimulant drugs, transcranial magnetic stimulation, brain-computer interfaces, and even genetic modifications are all discussed as forms of potential cognitive enhancement. Cognitive enhancement can be conceived as a benefit-seeking strategy used by healthy individuals to enhance cognitive abilities such as learning, memory, attention, or vigilance. This phenomenon is hotly debated in the public, professional, and scientific literature. Many of the statements favoring cognitive enhancement (e.g., related to greater productivity and autonomy) or opposing it (e.g., related to health-risks and social expectations) rely on claims about human welfare and human flourishing. But with real-world evidence from the social and psychological sciences often missing to support (or invalidate) these claims, the debate about cognitive enhancement is stalled. In this paper, we describe a set of crucial debated questions about psychological and social aspects of cognitive enhancement (e.g., intrinsic motivation, well-being) and explain why they are of fundamental importance to address in the cognitive enhancement debate and in future research. We propose studies targeting social and psychological outcomes associated with cognitive enhancers (e.g., stigmatization, burnout, mental well-being, work motivation). We also voice a call for scientific evidence, inclusive of but not limited to biological health outcomes, to thoroughly assess the impact of enhancement. This evidence is needed to engage in empirically informed policymaking, as well as to promote the mental and physical health of users and non-users of enhancement.

Citing Articles

"In the spectrum of people who are healthy": Views of individuals at risk of dementia on using neurotechnology for cognitive enhancement.

Beck A, Schonau A, MacDuffie K, Dasgupta I, Flynn G, Song D Neuroethics. 2025; 17(2.

PMID: 39790464 PMC: 11709137. DOI: 10.1007/s12152-024-09557-2.


Neurobiology and systems biology of stress resilience.

Kalisch R, Russo S, Muller M Physiol Rev. 2024; 104(3):1205-1263.

PMID: 38483288 PMC: 11381009. DOI: 10.1152/physrev.00042.2023.


Adapting Ourselves, Instead of the Environment: An Inquiry into Human Enhancement for Function and Beyond.

Dobler N, Carbon C Integr Psychol Behav Sci. 2023; 58(2):589-637.

PMID: 37597122 PMC: 11052783. DOI: 10.1007/s12124-023-09797-6.


Do Medical Universities Students Use Cognitive Enhancers while Learning?-Conclusions from the Study in Poland.

Merwid-Lad A, Passon M, Drymluch P, Gluszynski M, Szelag A, Matuszewska A Life (Basel). 2023; 13(3).

PMID: 36983975 PMC: 10056889. DOI: 10.3390/life13030820.


Cooperative behavior in the workplace: Empirical evidence from the agent-deed-consequences model of moral judgment.

Sattler S, Dubljevic V, Racine E Front Psychol. 2023; 13:1064442.

PMID: 36698601 PMC: 9869171. DOI: 10.3389/fpsyg.2022.1064442.


References
1.
Graf W, Nagel S, Epstein L, Miller G, Nass R, Larriviere D . Pediatric neuroenhancement: ethical, legal, social, and neurodevelopmental implications. Neurology. 2013; 80(13):1251-60. DOI: 10.1212/WNL.0b013e318289703b. View

2.
Battleday R, Brem A . Modafinil for cognitive neuroenhancement in healthy non-sleep-deprived subjects: A systematic review. Eur Neuropsychopharmacol. 2015; 25(11):1865-81. DOI: 10.1016/j.euroneuro.2015.07.028. View

3.
Ghahremani D, Tabibnia G, Monterosso J, Hellemann G, Poldrack R, London E . Effect of modafinil on learning and task-related brain activity in methamphetamine-dependent and healthy individuals. Neuropsychopharmacology. 2011; 36(5):950-9. PMC: 3077264. DOI: 10.1038/npp.2010.233. View

4.
Sample M, Aunos M, Blain-Moraes S, Bublitz C, Chandler J, Falk T . Brain-computer interfaces and personhood: interdisciplinary deliberations on neural technology. J Neural Eng. 2019; 16(6):063001. DOI: 10.1088/1741-2552/ab39cd. View

5.
Lavault S, Dauvilliers Y, Drouot X, Leu-Semenescu S, Golmard J, Lecendreux M . Benefit and risk of modafinil in idiopathic hypersomnia vs. narcolepsy with cataplexy. Sleep Med. 2011; 12(6):550-6. DOI: 10.1016/j.sleep.2011.03.010. View